We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 123

Pfizer v Ranbaxy; 55.2 proceeding; October 5, 2007 - atorvastatin

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 25 2007

The trial judge granted prohibition in respect of one patent claiming a novel crystalline form of atorvastatin (the "crystalline form patent") and denied prohibition in respect of another patent claiming a novel process for making atorvastatin (the "process patent"

PMPRB decisions and cases the year 2009 in review

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 3 2010

During 2009, a number of key decisions issued from panels of the Patented Medicine Prices Review Board (PMPRB) and the courts on issues relating to Canada's federal system of price control

Nycomed v Genpharm; s.6(5) motion; 55.2 proceeding; March 10, 2008; pantoprazole

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 21 2008

The second person brought a motion to dismiss the proceeding on the basis that the two patents were ineligible for listing and that, in addition, it would be abusive to proceed in respect of the second patent

Apotex v. Sanofi; interlocutory motion re: affidavits of documents; clopidogrel

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 12 2010

Both parties brought motions for further and better affidavits of documents

Eli Lilly and Company successful in patent infringement action against Apotex

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 2 2009

On October 1, 2009, Justice Gauthier of the Federal Court of Canada rendered a decision upholding the validity of eight process patents relating to intermediates used in the production of the antibiotic cefaclor

Pfizer v. ratiopharm Inc.; interlocutory motion on appeal of impeachment decision

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 3 2009

Pfizer filed a motion to amend the contents of its appeal book, its notice of appeal and its memorandum of fact and law on the appeal to deal with the additional grounds

Celgene v. Canada

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 24 2009

Celgene is the current owner of several patents relating to thalidomide

Sanofi-Aventis v. Laboratoire Riva; interlocutory motion on 55.2 proceeding; December 14, 2007 - Ramipril

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 17 2008

After cross-examinations had taken place, and approximately one week before the application record of Sanofi-Aventis was due, Riva brought a motion for leave to file further evidence

AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing

Lundbeck v. Cobalt, Genpharm and Apotex

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 7 2009

The Court granted prohibition in respect of each of the proceedings against each defendant